Table 1 Summary of outcome data for HER2 negative and HER2 2018 ASCO/CAP ISH group 4 and IHC2+ (IG4,2+) status patient cohort

From: Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer

Characteristics

HER2 negative, n = 47 (%)

HER2 IG4,2+, n = 13 (%)

P value

Treatment

   

 Chemotherapy

22 (46)

8 (61)

0.53

 Hormonotherapy

33 (70)

11 (85)

0.48

 Radiotherapy

28 (60)

5 (38)

0.22

 Trastuzumab

4 (9)

4 (31)

0.06

Recurrence

  

1.0

 Yes

7 (15)

2 (15)

 

 No

40 (85)

11 (85)

 

Survival

  

1.0

 Deceased

6 (13)

2 (15)

 

 Alive

41 (87)

11 (85)

 
  1. All statistical tests were two-sided Fisher’s exact test
  2. ASCO/CAP American Society of Clinical Oncology/College of American Pathologists, HER2 human epidermal growth factor receptor 2, ISH in situ hybridization
Back to article page